Solvonis Therapeutics plc (SVNS.L)
LSE · GBp · Healthcare · Biotechnology
£0.0935 (-1.58%) as of
Key statistics
- Market cap
- 6.36M
- Forward P/E
- -1.42
- EPS (TTM)
- -0.0000
- Dividend yield
- 0.00%
- 52-week range
- 0.0900 – 0.3400
- Beta
- 1.19
- Profit margin
- 0.00%
- Analyst target
- £1.70
- Volume
- 16.40M
About Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
- Employees
- 6
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.